Endocyte Inc is a biopharmaceutical Company developing targeted therapies for the treatment of cancer and inflammatory diseases. It uses its proprietary technology to create novel small molecule drug conjugates or SMDCs and companion imaging diagnose.


Updates from The Motley Fool

Latest updates on Endocyte from Fool.com.
Biotech Bad News Buys

It's pretty common to see a biotech tank on any given day, so when three companies dropped substa...

5 of Last Week's Biggest Losers

There's never a shortage of losers in the stock market. Let's take a closer look at five of this ...

Today's 3 Biotech Blow-Ups

While the Motley Fool believes investing should be a long term affair, investors should be aware ...

5 of Last Week's Biggest Winners

What's better than momentum? Mo' momentum. Let's take a closer look at five of this past week's b...



Stock Performance

View Interactive ECYT Charts
Sponsored by

Key Data Points

Primary metrics and data points about Endocyte.
Current Price: $2.75
Prev Close: $2.75
Open: $2.73
Bid: $2.74
Ask: $2.75
Day's Range: $2.64 - $2.77
52wk Range: $2.55 - $4.33
Volume: 104,755
Avg Vol 182,239
Market Cap: $115M
P/E (ttm): -2.89
EPS (ttm): ($0.95)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Endocyte.
CAPS Rating 4 out of 5
 
93 Outperform
9 Underperform
CAPS All Stars
 
21 Outperform
1 Underperform

How do you think Endocyte will perform against the market?



You pick for Endocyte is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


Business Summary

Industry, sector and description for Endocyte.

Endocyte Inc is a biopharmaceutical Company developing targeted therapies for the treatment of cancer and inflammatory diseases. It uses its proprietary technology to create novel small molecule drug conjugates or SMDCs and companion imaging diagnose.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers